OR01

Use and isolation of maternal milk exosomes: New vector for genetic hNIS therapy and diagnostic in oncology

A Crespo-Barreda(5) A Medel-Martínez(3,5) A Redrado-Osta(3) V Sebastián(2) E Iglesias(6) M Sancho-Albero(2) A de la Vieja(4) P Martin-Duque(1,2,3,5)

1:Fundación Araid; 2:Universidad de Zaragoza; 3:IIS Aragón; 4:Instituto de Salud Carlos III; 5:Instituto Aragonés de Ciencias de la Salud (IACS); 6:Universidad San Jorge

Nowadays, exosomes are merging as potential therapeutic tools acting as nanocarriers of molecules and drugs due to its capacity to carry bioactive molecules that can be transferred into surrounding and distal cells. Maternal milk contains large amounts of exosomes with a major therapeutic or immunomodulatory potential

 

NIS gene allows the accumulation of iodine in the areas where it is expressed (using with the positron emitter isotope I¹²⁴, to be visualized by PET), or as a therapeutic gene for the treatment of tumors, allowing the accumulation of therapeutic doses of radioisotopes such as I¹³¹. The high NIS expression on the breast while breastfeeding and the numerous exosomes obtained from maternal milk let us to think that the secretion of exosomes in maternal milk might lead to an endogenous NIS expression in those vesicles, and this could be translated into an antitumor and visualization potential or a therapeutic effect combined with I¹³¹.

 

We studied the migratory properties of exosomes from maternal milk towards different types of solid tumors, with a great success, targeting specifically the metastatic nodules with sharp precision

 

ACKNOWLEDGEMENTS: Instituto de Salud Carlos III (ISCIII) (PI19/01007 and DTS21/00130).